talkbio – Page 3

Nuvalent Reports Positive Pivotal Data for ROS1-Targeted Lung Cancer Drug; Rolling FDA Submission Planned

1 week ago talkbio0Tagged ARROS-1 trial, Frequency of Responses, Metastatic malignant neoplasm to brain, Neoplasms, Non-Small Cell Lung Carcinoma, Nuvalent, Protein-tyrosine kinase inhibitor, ROS1-positive Lung Cancer, Submission, United States Food and Drug Administration, zidesamtinib

Nuvalent; ROS1-positive lung cancer; zidesamtinib; FDA submission; ARROS-1 trial; NSCLC; tyrosine kinase inhibitor; objective response rate; brain metastases; oncology

BrightGene’s Dual GLP-1/GIP Agonist BGM0504 Shows Promise in Phase 2 Diabetes and Obesity Trials at ADA25

1 week ago talkbio0Tagged ADA25, BGM0504, BrightGene, Diabetes Mellitus, Non-Insulin-Dependent, GLP-1/GIP agonist, Glycosylated hemoglobin A, Obesity, semaglutide, Weight maintenance regimen

BrightGene; BGM0504; GLP-1/GIP agonist; ADA25; Type 2 diabetes; Obesity; Phase 2 clinical trial; weight management; HbA1c reduction; semaglutide; tirzepatide

Amgen Adjusts Phase 3 Dosing for MariTide After Midstage Side Effects Concerns

1 week ago talkbio0Tagged Adverse event, amgen, Clinical Trials, Dosage, Escalation, gastric inhibitory polypeptide receptor, GLP-1 receptor, MariTide, Obesity, Phase 3, Vomiting

Amgen; MariTide; Phase 3; obesity treatment; dose escalation; vomiting; adverse events; clinical trial; GLP-1 receptor; GIP receptor

Hims & Hers Stock Plunges 30% as Novo Nordisk Ends Wegovy Sales Deal

1 week ago talkbio0Tagged deceptive marketing, Glucagon-Like Peptide 1, Hims & Hers, Nordisk, partnership termination, stock plunge, Telemedicine, Wegovy, Weight-Loss Agents

Hims & Hers; stock plunge; Novo Nordisk; Wegovy; partnership termination; compounded GLP-1 drugs; deceptive marketing; telehealth; weight loss drugs

FDA Acting CDER Head Jacqueline Corrigan-Curay to Retire Amid Leadership Turnover

1 week ago talkbio0Tagged agency departures, CDER, Drug Regulations, Jacqueline Corrigan-Curay, Leadership, Personnel Turnover, Retirement, United States Food and Drug Administration

FDA; Jacqueline Corrigan-Curay; CDER; retirement; leadership turnover; drug regulation; agency departures

Sen. Bill Cassidy Calls for Deferral of CDC Vaccine Meeting After RFK Jr. Panel Shakeup

1 week ago talkbio0Tagged ACIP, Advisory Committees, Bill Cassidy, Centers for Disease Control and Prevention (U.S.), Confirmation, Deferred, HELP Committee, Policy, RFK Jr., Senate, Vaccines

Bill Cassidy; RFK Jr.; CDC; vaccine advisory committee; ACIP; confirmation; deferral; Senate HELP Committee; vaccine policy

BrightGene’s BGM0504 Outperforms Novo Nordisk’s Semaglutide in Diabetes Trial, Eyes Showdown with Zepbound

1 week ago talkbio0Tagged BGM0504, BrightGene, Clinical Trials, Diabetes, eli lilly, GLP-1/GIP receptor agonist, Glycosylated hemoglobin A, Nordisk, Obesity, semaglutide, Weight maintenance regimen, Zepbound

BrightGene; diabetes; GLP-1/GIP receptor agonist; BGM0504; semaglutide; Novo Nordisk; Eli Lilly; Zepbound; clinical trial; HbA1c reduction; obesity; weight management

Royalty Pharma Commits $2 Billion to Revolution Medicines for RAS Cancer Drug Development

1 week ago talkbio0Tagged Clinical Development, daraxonrasib, Neoplasms, Pharma, RAS, RAS cancer, Revolution Medicines, Royalty, secured debt, synthetic royalty

Royalty Pharma; Revolution Medicines; daraxonrasib; $2 billion funding; RAS cancer; synthetic royalty; secured debt; clinical development; oncology; biotech funding

Sanofi Licenses Formation Bio’s JAK/SYK Inhibitor Gusacitinib in $630M+ AI-Driven Deal

1 week ago talkbio0Tagged AI drug development, Anabolism, Bio, chronic hand eczema, gusacitinib, Indication of (contextual qualifier), JAK/SYK inhibitor, Libertas Bio, licensing agreement, sanofi

Sanofi; Formation Bio; gusacitinib; JAK/SYK inhibitor; AI drug development; Libertas Bio; deal; chronic hand eczema; new indication; licensing agreement

Illumina Acquires SomaLogic to Accelerate Proteomics Strategy with $350M Upfront

2 weeks ago talkbio0Tagged Acquisition, Biotechnology, Illumina, Proteomics, SomaLogic, Standard BioTools

Illumina; SomaLogic; Standard BioTools; proteomics; acquisition; biotechnology